Limits...
[(18)F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of LAPC4-CR Castration-Resistant Prostate Cancer Xenograft Model in Soft Tissue Compartments.

McCall KC, Cheng SC, Huang Y, Kohl NE, Tupper T, Van den Abbeele AD, Zukotynski KA, Sweeney CJ - Transl Oncol (2015)

Bottom Line: Preclinical xenograft models have contributed to advancing our understanding of the molecular basis of prostate cancer and to the development of targeted therapy.This study showed that [(18)F]-FDG-PET/CT could be used to image and assess glucose metabolism of LAPC4-CR xenografts in vivo.Further work can investigate the use of PET/CT to quantify the metabolic response of LAPC4-CR to novel agents and combination therapies using soft tissue and possibly bone compartment xenograft models.

View Article: PubMed Central - PubMed

Affiliation: Department of Imaging, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA; Center for Biomedical Imaging in Oncology (Lurie Family Imaging Center), Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA. Electronic address: kmccall@partners.org.

No MeSH data available.


Related in: MedlinePlus

[18F]-FDG metabolism in LAPC4-CR xenograft tumors compared to anatomic and metabolic tumor volume measured on PET/CT. Scatter plots show (a) [18F]-FDG metabolism versus anatomic tumor volume seen on CT and (b) [18F]-FDG metabolism versus metabolic tumor volume seen on PET. The symbols represent the day postimplantation of tumors: 35 days (squares), 43 days (triangles), 49 days (Xs), 84 days (crosses), and 98 days (circles). The best-fit linear correlations for the pooled data of the 13 xenograft tumors are also shown.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4487789&req=5

f0025: [18F]-FDG metabolism in LAPC4-CR xenograft tumors compared to anatomic and metabolic tumor volume measured on PET/CT. Scatter plots show (a) [18F]-FDG metabolism versus anatomic tumor volume seen on CT and (b) [18F]-FDG metabolism versus metabolic tumor volume seen on PET. The symbols represent the day postimplantation of tumors: 35 days (squares), 43 days (triangles), 49 days (Xs), 84 days (crosses), and 98 days (circles). The best-fit linear correlations for the pooled data of the 13 xenograft tumors are also shown.

Mentions: The mice showed the expected biodistribution of [18F]-FDG in normal tissues, with radiotracer uptake seen in cardiac muscle, cerebellum, and harderian glands as well as physiologic excretion via the kidneys and urinary bladder (Figure 2). There was homogeneous [18F]-FDG activity in the liver and skeletal muscle. There was moderate to high [18F]-FDG activity in the LAPC4-CR xenografts compared with adjacent soft tissue liver and muscle (Figure 3 and Table 1). The xenograft metabolism was 4 to 11 times higher than liver, 3 to 19 times higher than muscle (Table 1), and significantly higher than normal tissue (Wilcoxon signed-rank P value < .01, Figure 4). The intratumor heterogeneity, IQR of local metabolism in subregions within the xenografts, was 78 ± 39% (Table 1). The [18F]-FDG-PET/CT images of 12 tumors showed enhanced [18F]-FDG activity at the rim and a photopenic center suspicious of necrosis. The tumor with the smallest CT tumor volume, mouse ID# 04F01 with 81 mm3, did not show the imaging characteristics of a necrotic core; however, the [18F]-FDG metabolism in that tumor fell within the range of the other tumors (Figure 5A and Table 1).


[(18)F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of LAPC4-CR Castration-Resistant Prostate Cancer Xenograft Model in Soft Tissue Compartments.

McCall KC, Cheng SC, Huang Y, Kohl NE, Tupper T, Van den Abbeele AD, Zukotynski KA, Sweeney CJ - Transl Oncol (2015)

[18F]-FDG metabolism in LAPC4-CR xenograft tumors compared to anatomic and metabolic tumor volume measured on PET/CT. Scatter plots show (a) [18F]-FDG metabolism versus anatomic tumor volume seen on CT and (b) [18F]-FDG metabolism versus metabolic tumor volume seen on PET. The symbols represent the day postimplantation of tumors: 35 days (squares), 43 days (triangles), 49 days (Xs), 84 days (crosses), and 98 days (circles). The best-fit linear correlations for the pooled data of the 13 xenograft tumors are also shown.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4487789&req=5

f0025: [18F]-FDG metabolism in LAPC4-CR xenograft tumors compared to anatomic and metabolic tumor volume measured on PET/CT. Scatter plots show (a) [18F]-FDG metabolism versus anatomic tumor volume seen on CT and (b) [18F]-FDG metabolism versus metabolic tumor volume seen on PET. The symbols represent the day postimplantation of tumors: 35 days (squares), 43 days (triangles), 49 days (Xs), 84 days (crosses), and 98 days (circles). The best-fit linear correlations for the pooled data of the 13 xenograft tumors are also shown.
Mentions: The mice showed the expected biodistribution of [18F]-FDG in normal tissues, with radiotracer uptake seen in cardiac muscle, cerebellum, and harderian glands as well as physiologic excretion via the kidneys and urinary bladder (Figure 2). There was homogeneous [18F]-FDG activity in the liver and skeletal muscle. There was moderate to high [18F]-FDG activity in the LAPC4-CR xenografts compared with adjacent soft tissue liver and muscle (Figure 3 and Table 1). The xenograft metabolism was 4 to 11 times higher than liver, 3 to 19 times higher than muscle (Table 1), and significantly higher than normal tissue (Wilcoxon signed-rank P value < .01, Figure 4). The intratumor heterogeneity, IQR of local metabolism in subregions within the xenografts, was 78 ± 39% (Table 1). The [18F]-FDG-PET/CT images of 12 tumors showed enhanced [18F]-FDG activity at the rim and a photopenic center suspicious of necrosis. The tumor with the smallest CT tumor volume, mouse ID# 04F01 with 81 mm3, did not show the imaging characteristics of a necrotic core; however, the [18F]-FDG metabolism in that tumor fell within the range of the other tumors (Figure 5A and Table 1).

Bottom Line: Preclinical xenograft models have contributed to advancing our understanding of the molecular basis of prostate cancer and to the development of targeted therapy.This study showed that [(18)F]-FDG-PET/CT could be used to image and assess glucose metabolism of LAPC4-CR xenografts in vivo.Further work can investigate the use of PET/CT to quantify the metabolic response of LAPC4-CR to novel agents and combination therapies using soft tissue and possibly bone compartment xenograft models.

View Article: PubMed Central - PubMed

Affiliation: Department of Imaging, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA; Center for Biomedical Imaging in Oncology (Lurie Family Imaging Center), Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA. Electronic address: kmccall@partners.org.

No MeSH data available.


Related in: MedlinePlus